Hydrix Limited · ASX:HYD
Hydrix — Shareholder Meeting (November 2023)
12 slides from Hydrix's shareholder meeting presentation, Nov 13, 2023
Slide 1: Medical technology innovation AGM Presentation
For personal use only Medical technology innovation AGM Presentation ASX : HYD 13 November 2023
Slide 2: About us
For personal use only About us: We create, invest in, and deliver the innovation in breakthrough technologies….to transform lives Top: Artificial Heart (TAH) under development by Scandinavian Realheart Bottom: TAH controller under development by Hydrix 2 |
Slide 3: Recap FY23 business highlights & milestones
HYDRIX Services HYDRIX Ventures Recap FY23 • Revenues $13.2m • Net Tangible Asset value business highlights (+34% fee revenues) increased 27% to $4.89m For personal use only & milestones • EU & US revenues $7.25m (up 4x pcp FY21) • Capital raising revaluations, equity in-kind milestone achievements
Slide 4: A 'buy, build, invest' strategy to sustained profitable growth
A 'buy, build, invest' strategy to For personal use only sustained profitable growth 01 02 03 04 05 06 Acquire Hydrix Establish Hydrix Establish Hydrix Build Medical Group Revenue Group Services Ventures Medical Portfolio Growth Profitability Secret Sauce Value Capture Growth Catalyst Products Licen
Slide 5: We create the innovation in breakthrough technologies
We create the innovation in breakthrough technologies For personal use only Michael Trieu Peter Riddell Pauline Newman General Manager Global Head of Business Lead Program Manager Development Market focus • Safety critical systems e.g., artificial heart / VAD control systems • Growth sectors: cardia
Slide 6: We invest in the innovation in breakthrough technologies
We invest in the innovation in breakthrough technologies For personal use only Gavin Coote Paul Kelly Alan Morris Executive Chairman Cardiac Product Strategy Global Marketing Director Ventures & Medical Portfolio Strategy • Early-stage, minority investment in clients developing world-first breakthro
Slide 7: We deliver the innovation in breakthrough technologies
We deliver the innovation in breakthrough technologies For personal use only Vickie Edwards James MacTaggart Deb White Director of Sales & Operations Sales and Clinical Manager Sales and Clinical Manager Market focus • Cardiovascular disease afflicts 14% of the population, is the leading cause of de
Slide 8: A group priority: Innovation in cardiac health
A group priority For personal use only Innovation in cardiac health Medical 45% of Services client fee revenues from Cardiovascular disease cardiovascular companies, e.g. total artificial Ventures (CVD) is the leading cause heart control devices, vascular robotics High potential early- of death glob
Slide 9: Goals for next 12 months
HYDRIX Services HYDRIX Ventures Goals for • >10% revenue growth primarily • Avertix – scale USA revenues, next 12 months from international sales growth revisit a CY24 IPO For personal use only • More than double FY23 cash • Initial sales of Gyder in operating profit Australia, commence US FDA regul
Slide 10: Key takeaways
Key takeaways For personal use only 1 Business in good hands, experienced leadership 2 Services FY23 profitable, strong revenue growth 3 Ventures assets are maturing, commercialising 4 Medical product sales coming, growth catalyst 5 Tracking to strategy, market value yet to catch up 10 |
Slide 11: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Hydrix Limited (the expectations are based on reasonable assumptions, it can whatsoever for: (a) investment advice; (b) a “Company” or “Hydrix”). This presentation is being provided give no assurance that its goals will be achie
Slide 12: For more information, please visit
For personal use only For more information, please visit: www.hydrix.com